Viron to Present Data from Phase II Trial at American Heart Association Conference
Viron to Present Data from Phase II Trial at American Heart Association Conference
About this item
Full title
Viron to Present Data from Phase II Trial at American Heart Association Conference
Publisher
Ottawa: PR Newswire Association LLC
Journal title
Canada NewsWire, 2009
Language
English
Formats
Publication information
Publisher
Ottawa: PR Newswire Association LLC
Subjects
More information
Scope and Contents
Contents
VT-111, an immune-modulating protein therapeutic, is the world's first viral-derived human therapeutic. It is a novel inhibitor of the monocyte/macrophage influx to sites of injury and has demonstrated potent efficacy in preclinical models of acute injury in which inflammation plays a key role. VT-111 recently completed a Phase IIa trial of 48 pati...
Alternative Titles
Full title
Viron to Present Data from Phase II Trial at American Heart Association Conference
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_wirefeeds_455135931
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_wirefeeds_455135931
How to access this item
Log in as a Library member
